We are committed to building a pipeline of products to address a range of neurological diseases
On February 1, 2021, the FDA approved a second indication for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes
To learn more please read our press release.
ADS-4101 in development for the treatment of partial onset seizures in patients with epilepsy (program paused)
ADS-4101 is an investigational high-dose, modified release lacosamide capsule, taken once-daily at bedtime. Lacosamide is an anti-epilepsy active ingredient previously approved by the FDA and currently marketed by UCB SA/NV as VIMPAT® (lacosamide).
The ADS-4101 development program is currently paused as we are evaluating the potential value and options for a path forward for this candidate.
“People are sometimes told to go home and find a comfortable chair. Well, I decided early on to do the opposite.”
– John, person with Parkinson’s, determined runner and PD fundraiser